C.M. Bidwell & Associates’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$321K Sell
11,421
-67
-0.6% -$1.78K 0.15% 84
2025
Q4
$286K Sell
11,488
-387
-3% -$9.76K 0.14% 102
2025
Q3
$303K Sell
11,875
-892
-7% -$22K 0.15% 89
2025
Q2
$309K Sell
12,767
-630
-5% -$14.7K 0.16% 89
2025
Q1
$339K Sell
13,397
-223
-2% -$5.83K 0.2% 84
2024
Q4
$361K Buy
13,620
+2,900
+27% +$78.7K 0.22% 76
2024
Q3
$310K Buy
+10,720
New +$313K 0.19% 86
2022
Q3
Sell
-6,022
Closed -$316K 524
2022
Q2
$316K Sell
6,022
-2,415
-29% -$123K 0.25% 64
2022
Q1
$437K Sell
8,437
-198
-2% -$10.3K 0.29% 56
2021
Q4
$510K Buy
+8,635
New +$428K 0.31% 50
2019
Q3
Sell
-11,757
Closed -$483K 470
2019
Q2
$483K Buy
11,757
+10,940
+1,339% +$434K 0.48% 54
2019
Q1
$33K Hold
817
0.03% 279
2018
Q4
$34K Buy
+817
New +$33.9K 0.04% 269
2017
Q1
Sell
-118
Closed -$4K 280
2016
Q4
$4K Sell
118
-130,615
-100% -$3.99M ﹤0.01% 225
2016
Q3
$4.2M Sell
130,733
-395
-0.3% -$13.2K 1% 31
2016
Q2
$4.38M Sell
131,128
-106
-0.1% -$3.38K 1.09% 21
2016
Q1
$3.69M Buy
+131,234
New +$3.75M 0.92% 55
2014
Q2
Sell
-1,697
Closed -$52K 280
2014
Q1
$52K Sell
1,697
-79,946
-98% -$2.38M 0.01% 202
2013
Q4
$2.37M Sell
81,643
-284
-0.3% -$8.27K 0.59% 83
2013
Q3
$2.23M Buy
81,927
+295
+0.4% +$8.03K 0.61% 84
2013
Q2
$2.17M Buy
+81,632
New +$2.26M 0.64% 80

Other funds holding PFE

C.M. Bidwell & Associates's PFE Position: Q1 2026 in Review

C.M. Bidwell & Associates reduced its Pfizer (PFE) stake by 0.58% in Q1 2026, selling an estimated $1.78K and leaving 11,421 shares worth $321K. The position accounts for 0.15% of the portfolio, ranked #84.

C.M. Bidwell & Associates first reported a position in PFE in Q2 2013 and has held it in 21 quarters since. The position peaked at $4.38M in Q2 2016. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • C.M. Bidwell & Associates held 11,421 shares of Pfizer worth $321K as of Q1 2026.
  • C.M. Bidwell & Associates sold 67 Pfizer shares in Q1 2026, an estimated $1.78K.
  • Pfizer made up 0.15% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #84 holding.
  • C.M. Bidwell & Associates first reported a position in Pfizer in Q2 2013 and has held it in 21 quarters since.
  • C.M. Bidwell & Associates's Pfizer position peaked at $4.38M in Q2 2016.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.